24Nov
15Dec
Boston Harbor Angels Awards Portfolio Companies at Annual Meeting
Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting. Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc. IT Startup of the Year Award: Wasabi The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi. The group also honored Mic Williams,...
02Sep
NFL’s New Concussion Pill Could Be Filled With CBD
Although the search for a concussion pill is merely in the “mouse model” phase, significant strides have been made by researchers. Dr. William Korinek, the CEO of Astrocyte Pharmaceuticals, believes such a pill can arrive as early as 2025. Dr. Kun Ping Lu, a doctor researching a possible medication to destroy compounds that cause brain damage, has a slightly-less optimistic time frame. He believes a possible pill could arrive within the next ten years. Read more >>
02Sep
The Race Is on for a ‘Concussion Pill’ as New NFL Season Begins
The "concussion pill" may be coming soon. "This is coming in 2025 if all goes well," Dr. William Korinek, the CEO of Astrocyte Pharmaceuticals, said of a drug that turbocharges the brain's ability to heal its own damage. Read more >>
19Jul
Drug for concussion, stroke found by UT scientist moves closer to human trials
Astrocyte Pharmaceuticals, the company Lechleiter founded with William Korinek of Boston, completed Monday its first round of financing that raised roughly $2.4 million in fresh capital. The fledgling company had $670,000 in seed funding from the federal government since 2014. Lechleiter hopes the drug, which is at least 7 years away from market, could be easily administered by any football coach or paramedic to mitigate the effects of concussions or strokes. Read more >>
28Mar
Boston Harbor Angels Bet on New Frontier in Neuroscience
Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson's Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly. Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI,...
25Mar